Acquisition of specific antibodies and their influence on cell-mediated immune response in neonatal cord blood after maternal pertussis vaccination during pregnancy

Imagem de Miniatura
Arquivos
art_LIMA_Acquisition_of_specific_antibodies_and_their_influence_on_2019.PDF (618.37 KB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2019
Editora
ELSEVIER SCI LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
MOLINA, Mariela da Gama Fortunato
NADAF, Marvin Lucas Ale
NADAF, Maria Isabel Valdomir
TAKANO, Olga Akiko
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
VACCINE, v.37, n.19, p.2569-2579, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Maternal immunization with pertussis acellular vaccine (Tdap) is an intervention that provides protection to newborns. However, it has been reported that high maternal antibody levels may adversely affect the immune response of infants after active immunization. In this study, we evaluated neonatal passive acquisition of pertussis-specific antibodies and their influence on the neonatal cell-mediated immune response. Pregnant women were either vaccinated with Tdap vaccine (case group, n = 66) or received no vaccine (control group, n = 101). Whole-cell Bordetella pertussis (Bp), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)-specific serum IgG were quantified in paired maternal-cord sera, and Bp- and PT-specific IgA were evaluated in colostrum by ELISA. Ex vivo neonatal blood lymphocyte responsiveness after Bp stimulation was assessed in case (n = 17) and control (n = 15) groups using flow cytometry to detect proliferation, cytokine production and activation phenotype of lymphocytes in the context of high specific IgG acquired after maternal vaccination. Anti-Bp, PT, FHA and PRN IgG concentrations in maternal and cord sera from case group were higher than those in control group with positive correlation indexes in both groups for all pertussis antigens. The control group presented higher placental transfer ratios of specific antibodies and, in the case group, vaccination between 26 and 31 gestation weeks was associated with the best placental transfer ratios. Specific IgA concentrations in colostrum were not affected by vaccine status. Whole blood assays revealed that newborns responded to Bp stimulation with higher expression of CD40L, CD69 and CD4(+) T cell proliferation compared to unstimulated cells, and a lower Thl response, while a preserved Th2 response compared to adults, but there were no differences between the neonatal groups for any of the studied parameters. Our results indicate that higher pertussis-specific IgG levels in newborn sera after maternal vaccination do not affect the neonatal ex vivo cell-mediated immune response.
Palavras-chave
Bordetella pertussis, Tdap vaccine in pregnancy, IgG placental transfer, Neonatal T-cell response
URI
https://observatorio.fm.usp.br/handle/OPI/31884
Referências
  1. Abu Raya B, 2014, VACCINE, V32, P5632, DOI 10.1016/j.vaccine.2014.08.006
  2. Agarwal S, 2011, J HUM LACT, V27, P171, DOI 10.1177/0890334410395761
  3. Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288
  4. Boulton Jacqueline, 2013, Br J Nurs, V22, P1046
  5. Carbonetti NH, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv073
  6. Carollo M, 2012, VACCINE, V30, P1667, DOI 10.1016/j.vaccine.2011.12.104
  7. Denkinger CM, 2007, CELL IMMUNOL, V246, P46, DOI 10.1016/j.cellimm.2007.05.004
  8. Dirix V, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/795958
  9. Dubin PJ, 2008, IMMUNOL REV, V226, P160, DOI 10.1111/j.1600-065X.2008.00703.x
  10. Englund JA, 2007, J COMP PATHOL, V137, pS16, DOI 10.1016/j.jcpa.2007.04.006
  11. Goenka A, 2015, J INFECTION, V71, pS112, DOI 10.1016/j.jinf.2015.04.027
  12. Grondahl-Yli-Hannuksela K, 2016, VACCINE, V34, P341, DOI 10.1016/j.vaccine.2015.11.049
  13. Hoang HTT, 2016, VACCINE, V34, P151, DOI 10.1016/j.vaccine.2015.10.098
  14. Healy CM, 2007, PEDIATR INFECT DIS J, V26, P945, DOI 10.1097/INF.0b013e318156c18c
  15. Hodder SL, 2000, CLIN INFECT DIS, V31, P7, DOI 10.1086/313913
  16. Jones C, 2014, VACCINE, V32, P996, DOI 10.1016/j.vaccine.2013.11.104
  17. Le Doare K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01269
  18. Maertens K, 2014, VACCINE, V32, P1786, DOI 10.1016/j.vaccine.2014.01.083
  19. Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005
  20. McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288
  21. Mills KHG, 2001, MICROBES INFECT, V3, P655, DOI 10.1016/S1286-4579(01)01421-6
  22. Ministerio da Saude (BR). Secretaria de Vigilancia em Saude, 2015, B EPIDEMIOL, V46, P1
  23. Miyano Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064777
  24. Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
  25. Nagao AT, 1998, SCAND J IMMUNOL, V47, P609
  26. Naidu MA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.03.002
  27. Nieves DJ, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.EI10-0008-2015
  28. Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
  29. Palazzo R, 2016, NEW MICROBIOL, V39, P35
  30. Palmeira P, 2016, REV ASSOC MED BRAS, V62, P584, DOI 10.1590/1806-9282.62.06.584
  31. Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646
  32. Pandolfi E, 2017, PEDIATR INFECT DIS J, V36, pE48, DOI 10.1097/INF.0000000000001418
  33. Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
  34. Quinello C, 2010, SCAND J IMMUNOL, V72, P66, DOI 10.1111/j.1365-3083.2010.02410.x
  35. Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011
  36. Raya B. A., 2014, Vaccine, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038
  37. Saso A, 2017, SEMIN IMMUNOPATHOL, V39, P627, DOI 10.1007/s00281-017-0654-9
  38. Shahid NS, 2002, VACCINE, V20, P2404, DOI 10.1016/S0264-410X(02)00061-0
  39. Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6
  40. Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7
  41. Smits K, 2013, VACCINE, V32, P111, DOI 10.1016/j.vaccine.2013.10.056
  42. Soares A, 2010, J IMMUNOL METHODS, V362, P43, DOI 10.1016/j.jim.2010.08.007
  43. Vermeulen F, 2010, CLIN VACCINE IMMUNOL, V17, P258, DOI 10.1128/CVI.00328-09
  44. WHICHER JT, 1983, CRC CR REV CL LAB SC, V18, P213
  45. Winter K, 2012, J PEDIATR-US, V161, P1091, DOI 10.1016/j.jpeds.2012.05.041
  46. Wolfe DN, 2007, J INFECT DIS, V196, P1228, DOI 10.1086/521303
  47. World Health Organization, 2016, VACC PREV DIS MON SY
  48. 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/CID/CIU821
  49. 2013, PEDIATR INFECT DIS J, V32, P1257, DOI 10.1097/INF.0B013E3182A09B6A

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/36
Artigos e Materiais de Revistas Científicas - LIM/43
Artigos e Materiais de Revistas Científicas - ODS/03